CClinicalTrials.gg
RecruitingNCT07315178ADEPTUpdated Jan 2, 2026

Creation of a Digital Twin for Predicting the Progression of Patients With Chronic Thoracic Aortic Dissection

An interventional study of MRI with 4D flow imaging and blood sampling in Type A Aortic Dissection With Residual Type B Dissection and Chronic Type B Aortic Dissection, sponsored by Centre Hospitalier Universitaire Dijon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Centre Hospitalier Universitaire Dijon · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Nov 2025; still recruiting 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Aortic dissection causes a tear in the inner layers of the aorta, leading to the formation of a true and false lumen.

There are two types of dissection: type A, which affects the ascending aorta, and type B, which affects the descending aorta. Type A aortic dissection is almost always a surgical emergency and involves replacing the ascending aorta with a prosthesis. After this type of dissection, a residual dissection remains in the descending aorta, known as residual type B dissection, which becomes chronic. This requires increased monitoring by MRI or CT scan, which are currently not effective enough to predict the development of an aneurysm that could lead to aortic rupture requiring surgical intervention. Other factors such as blood flow, the forces and mechanisms regulating blood circulation, the mechanics and histology of the aorta, and blood markers could provide a more reliable prediction of the development of an aneurysm. The creation of a digital twin model incorporating all these factors should enable better patient management.

02

Conditions studied

  • Type A Aortic Dissection With Residual Type B Dissection
  • Chronic Type B Aortic Dissection
03

In context

Lead sponsor

Centre Hospitalier Universitaire Dijon is the lead sponsor of 495 studies on the registry; 105 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Person who has given written consent
  • Age > 18 years
  • Patient with type A aortic dissection with surgical indication for replacement
  • Patient with chronic type B aortic dissection, monitored and managed medically, not operated on

Exclusion criteria

Exclusion Criteria:

  • Persons not affiliated with or not covered by a social security scheme
  • Persons subject to legal protection measures (guardianship)
  • Persons subject to judicial protection measures
  • Pregnant women, women in labour or breastfeeding
  • Adults who are incapacitated or unable to give their consent
  • Contraindications to MRI: claustrophobia, non-MRI-compatible metal implants, suspected metal foreign body
  • Severe renal failure (clearance \<30ml/min according to Cockroft due to gadolinium injection)
  • Uncontrolled asthma
  • Patients with acute type A aortic dissection who died during or in the post-operative period following surgery to repair the dissection
  • Patients with a known allergy to gadolinium-based contrast agents
  • Patients treated for type B aortic dissection who underwent surgery
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Type B aortic dissection

    Other: MRI with 4D flow imaging · Biological: blood sampling

  • Experimental
    Residual type B aortic dissection following surgery for type A aortic dissection

    Other: MRI with 4D flow imaging · Biological: blood sampling

Interventions

  • OtherMRI with 4D flow imaging

    At 3 months

  • Biologicalblood sampling

    2 tubes of 10 ml blood at inclusion, at 3 months, at 12 months, at 24 months and at 36 months

06

What researchers measure

Primary outcomes

  1. Relevance of combining biomarkers

    Time frame: 3 months, 1 year, 2 years, 3 years

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07315178
Lead sponsor
Centre Hospitalier Universitaire Dijon
Responsible party
Sponsor
First posted
Jan 2, 2026
Start date
Nov 25, 2025
Primary completion
Nov 2031 (estimated)
Completion
Nov 2031 (estimated)
Last update
Jan 2, 2026

Study contacts

Alain Lalande
Contact
alain.lalande@u-bourgogne.fr

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion